Fig. 6: Cilta-cel patients with atypical neurotoxicity show CNS infiltration by effector memory-type CART cells producing an inflammatory cytokine signature. | Nature Communications

Fig. 6: Cilta-cel patients with atypical neurotoxicity show CNS infiltration by effector memory-type CART cells producing an inflammatory cytokine signature.

From: Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

Fig. 6

A Analysis of BCMA-targeted CAR T cell numbers in the peripheral blood (PB) and the cerebrospinal fluid (CSF) from the same timepoint after CART infusion in three myeloma patients who had developed unusual types of neurotoxicity around 3-4 weeks after cilta-cel infusion. Analyses were performed by flow cytometry following co-staining with anti-CD3 and BCMA CAR detection reagent which represents a fluorescent, full-length, recombinant BCMA protein binding to the CAR expressed on the cell surface. B CAR T cell subpopulations in the PB and CSF were determined following staining with anti-CD4 and anti-CD8 monoclonal antibodies. C Different CAR T memory subpopulations in the PB and CSF were identified by flow cytometry using co-staining with anti-CD45RA and anti-CD62L monoclonal antibodies. D The concentration of 22 cytokines/chemokines were measured in the PB and the CSF from the same sample of all three patients using CodePlex Secretome technology. Results are shown as absolute concentrations in pg/mL. Source data are provided as a Source Data file.

Back to article page